250 related articles for article (PubMed ID: 8255478)
21. COMT inhibition: a new treatment strategy for Parkinson's disease.
Kurth MC; Adler CH
Neurology; 1998 May; 50(5 Suppl 5):S3-14. PubMed ID: 9591516
[TBL] [Abstract][Full Text] [Related]
22. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation.
Jorga K; Fotteler B; Sedek G; Nielsen T; Aitken J
J Neurol; 1998 Apr; 245(4):223-30. PubMed ID: 9591224
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.
Baas H; Zehrden F; Selzer R; Kohnen R; Loetsch J; Harder S
Clin Pharmacokinet; 2001; 40(5):383-93. PubMed ID: 11432539
[TBL] [Abstract][Full Text] [Related]
24. Highlights of the North American and European experiences.
Goetz CG
Neurology; 1998 May; 50(5 Suppl 5):S15-6. PubMed ID: 9591517
[TBL] [Abstract][Full Text] [Related]
25. Tolcapone in the management of Parkinson's disease.
Leegwater-Kim J; Waters C
Expert Opin Pharmacother; 2006 Nov; 7(16):2263-70. PubMed ID: 17059382
[TBL] [Abstract][Full Text] [Related]
26. [Tolcapone: a different, effective approach to improving dopaminergic treatment in Parkinson's disease].
Kulisevsky J
Neurologia; 1998 Feb; 13(2):74-82. PubMed ID: 9578674
[TBL] [Abstract][Full Text] [Related]
27. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.
Borges N
Expert Opin Drug Saf; 2005 Jan; 4(1):69-73. PubMed ID: 15709899
[TBL] [Abstract][Full Text] [Related]
28. Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression.
Männistö PT; Lang A; Rauhala P; Vasar E
Eur J Pharmacol; 1995 Feb; 274(1-3):229-33. PubMed ID: 7768276
[TBL] [Abstract][Full Text] [Related]
29. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group.
Waters CH; Kurth M; Bailey P; Shulman LM; LeWitt P; Dorflinger E; Deptula D; Pedder S
Neurology; 1998 May; 50(5 Suppl 5):S39-45. PubMed ID: 9591521
[TBL] [Abstract][Full Text] [Related]
30. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement.
Tohgi H; Abe T; Yamazaki K; Saheki M; Takahashi S; Tsukamoto Y
Neurosci Lett; 1995 Jun; 192(3):165-8. PubMed ID: 7566641
[TBL] [Abstract][Full Text] [Related]
31. Extending levodopa action: COMT inhibition.
Martínez-Martín P; O'Brien CF
Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
[TBL] [Abstract][Full Text] [Related]
32. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial.
Rajput AH; Martin W; Saint-Hilaire MH; Dorflinger E; Pedder S
Neurology; 1997 Oct; 49(4):1066-71. PubMed ID: 9339691
[TBL] [Abstract][Full Text] [Related]
33. Tolcapone: a novel approach to Parkinson's disease.
Micek ST; Ernst ME
Am J Health Syst Pharm; 1999 Nov; 56(21):2195-205. PubMed ID: 10565698
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies.
Jorga K; Fotteler B; Banken L; Snell P; Steimer JL
Br J Clin Pharmacol; 2000 Jan; 49(1):39-48. PubMed ID: 10606836
[TBL] [Abstract][Full Text] [Related]
35. Influence of COMT inhibition on levodopa pharmacology and therapy.
Goetz CG
Neurology; 1998 May; 50(5 Suppl 5):S26-30. PubMed ID: 9591519
[TBL] [Abstract][Full Text] [Related]
36. Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline.
Davis TL; Roznoski M; Burns RS
Clin Neuropharmacol; 1995 Aug; 18(4):333-7. PubMed ID: 8665546
[TBL] [Abstract][Full Text] [Related]
37. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.
Chong DJ; Suchowersky O; Szumlanski C; Weinshilboum RM; Brant R; Campbell NR
Clin Neuropharmacol; 2000; 23(3):143-8. PubMed ID: 10895397
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers.
Jorga KM
Neurology; 1998 May; 50(5 Suppl 5):S31-8. PubMed ID: 9591520
[TBL] [Abstract][Full Text] [Related]
39. Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease.
Sabaté M; Bosch A; Pedrós C; Figueras A
Ann Pharmacother; 1999 Nov; 33(11):1228-9. PubMed ID: 10573327
[No Abstract] [Full Text] [Related]
40. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects.
Dingemanse J; Jorga K; Zürcher G; Fotteler B; Sedek G; Nielsen T; van Brummelen P
Eur J Clin Pharmacol; 1996; 50(1-2):47-55. PubMed ID: 8739811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
